Active	Status	Sponsor type	Region	Phase	Filter
3 Active 5 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Liesveld, Jane L
NCT03258931: Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML	Recruiting	3	510	US	Crenolanib, Crenolanib besylate, Midostaurin, Cytarabine, Duanorubicin	Arog Pharmaceuticals, Inc.	Newly Diagnosed FLT3 Mutated AML	11/22	11/24